Antipsychotic‑Associated Stroke Risk and Monitoring

Mechanisms Contributing to Stroke

Antipsychotic drugs can precipitate embolic stroke by prolonging the QT interval through potassium‑channel blockade, which may trigger torsades de pointes and other ventricular arrhythmias【1】【2】.
When the corrected QT interval exceeds 500 ms or rises by more than 60 ms from baseline, dose reduction or discontinuation is recommended to mitigate arrhythmic and stroke risk【1】.
Use of antipsychotics is associated with a 1.53‑fold increase in ventricular arrhythmia and sudden cardiac death; agents that are strong potassium‑channel blockers carry the highest risk【1】.
Orthostatic hypotension caused by α‑1‑adrenergic blockade reduces cerebral perfusion pressure and can produce watershed infarcts, particularly in older adults with pre‑existing cerebrovascular disease【3】【1】.
Metabolic disturbances—including weight gain, hyperglycemia, and new‑onset diabetes—induced by second‑generation antipsychotics add established stroke risk factors; screening is advised at baseline, 12–16 weeks, and annually【4】.

First‑generation (typical) antipsychotics as a class raise the risk of ventricular arrhythmia/sudden cardiac death by 1.66‑fold; chlorpromazine, thioridazine, and haloperidol have especially high cardiovascular risk【1】【3】.
Clozapine increases stroke risk approximately 2.03‑fold, quetiapine 1.29‑fold, and risperidone 1.39‑fold compared with patients not receiving antipsychotics【1】.
Aripiprazole and ziprasidone exhibit fewer metabolic effects and a comparatively lower stroke risk relative to other atypicals【4】【1】.

Electrocardiographic surveillance – obtain a baseline ECG, repeat QT assessments during dose titration, and discontinue or adjust therapy if QTc > 500 ms or rises >60 ms; also monitor serum potassium to avoid hypokalaemia that worsens QT prolongation【1】.
Metabolic monitoring – screen for diabetes at treatment start, at 12–16 weeks, and yearly thereafter; regularly assess weight, lipid profile, and glucose levels to detect metabolic syndrome early【4】.
Cardiovascular assessment – measure blood pressure for orthostatic changes, especially in older patients, and avoid co‑prescribing other QT‑prolonging medications, which synergistically increase arrhythmia and stroke risk【3】【1】.